Amgen has been battling a storm of generics and biosimilars—and last year posted a sales decline. But it still awarded its chief executive a total pay increase of more than $1 million. Why? Advances elsewhere, the company’s proxy says.
More: Amgen's sales slid in 2019. So why did CEO Bradway score a M-plus raise?